Find us on:
News
April 22, 2013 - Gallus BioPharmaceuticals Presents Real World Date From Its "Factory of the Future"
February 26, 2013 - Gallus BioPharmaceuticals Announces Addition of Senior Industry Leader to Its Board of Directors
January 22, 2013 - Gallus BioPharmaceuticals announces a new collaboration with Refine Technologies to optimize continuous cell culture processes.
October 24, 2012 - Mediomics LLC Receives Phase II SBIR Contract: Awarded $997,251 to Develop New In-Process Analyzer for Biologics
September 18, 2012 - Gallus BioPharmaceuticals and Roslin Cells Announce an Exclusive Partnership to Supply Cell Therapies for Clients
August 14, 2012 - Gallus BioPharmaceuticals Announces Collaboration Agreement with Natrix Separations Inc.
May 24, 2012 - Gallus BioPharmaceuticals Completes Initial $20 Million Expansion of Early-Phase Clinical Manufacturing Facility
May 15, 2012 - Gallus BioPharmaceuticals's Virtual Ownership Model Thrives with SAP Business All in One
Upcoming Events
June 23-26, 2013 - European Society for Animal Cell Technology - Lille, France
July 1-2, 2013 - World Biopharm Forum - Robinson College Cambridge, UK
Sep 16-19, 2013 - BioProcess International - Hynes Convention Center, Boston, MA
Sep 17-19, 2013 - Annual BioPharm America - Westin Boston Waterfront, Boston, MA
Oct 22-23, 2013 - Informa Flexible Facilities & Manufacturing of the Future - The Burlington Hotel, Dublin, Ireland
Oct 22-24, 2013 - CPHI/ICSE - Messe Frankfurt, Germany
Nov 3-6, 2013 - ISPE, Annual Meeting - Hynes Convention Center, Washington, DC
Nov 4-6, 2013 - BIO-Europe 2013 - Westin Boston Waterfront - Vienna, Austria
Nov 18-19, 2013 - Annual Bio-Development Global Congress - Boston, MA
Welcome to Gallus BioPharmaceuticals
Gallus BioPharmaceuticals delivers end-to-end biologics process development and cGMP drug manufacturing for pre-clinical, clinical and commercial stages for pharmaceutical, biotechnology and government organizations.
Unlike conventional contract manufactures, we empower you – our customers – by accelerating your time to market through personal symbiotic collaboration and virtual ownership models driven by advanced single-use technologies. Our sweeping approval from every major regulatory body across the globe, including the FDA, EMA, HealthCanada, ANVISA and PMDA, ultimately makes us the ideal partner for your entire suite of contract manufacturing needs.
Discover your own SuiteSPACE™
SuiteSPACE™ is Gallus's unique virtual ownership solution, designed to empower your drug manufacturing and mammalian cell culture processes. Supported by our experienced scientific team, SuiteSPACE™ captures the feeling of having your own facility while providing the flexibility you crave. The facility is specially tailored to meet and more easily adapt to your project’s specific needs. For more information, Contact Us.